Editor's Summary
17 September 2009
Individual responses to hepatitis C virus
Hepatitis C is one of the most common infections in the world. Many of its estimated 170 million sufferers live with the disease for years with no serious symptoms, but in about one in four patients it leads to cirrhosis of the liver. The discovery of a biomarker that predicts an individual's response to hepatitis C treatment raises the possibility that clinical outcomes could be improved by raising patient compliance to the often demanding interferon treatment regime. The new marker is a 'single letter' genetic variant — a C (cytosine) replacing a T (thymidine) in a segment of DNA near the IL28B gene that encodes interleukin 28B (interferon-
-3). This finding goes some way towards explaining the different treatment outcomes between individuals of European (high IL28B frequency), African and Asian ancestry. And importantly, it is of immediate clinical utility.
News and Views: Genomics: Hepatitis C virus gets personal
Many people infected with the hepatitis C virus are not cured despite gruelling therapy. A human genetic variant that predicts successful treatment has been identified. So is personalized therapy now a possibility?
Shawn P. Iadonato & Michael G. Katze
doi:10.1038/461357a
Letter: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge, Jacques Fellay, Alexander J. Thompson, Jason S. Simon, Kevin V. Shianna, Thomas J. Urban, Erin L. Heinzen, Ping Qiu, Arthur H. Bertelsen, Andrew J. Muir, Mark Sulkowski, John G. McHutchison & David B. Goldstein
doi:10.1038/nature08309
First paragraph | Full Text | PDF (393K) | Supplementary information
